^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Nectin-4-targeted peptide-drug conjugate

    Related drugs:
    3ms
    Study SC-101 in Subjects With Advanced Malignancies (clinicaltrials.gov)
    P1, N=100, Recruiting, Tianjin ConjuStar Biologics Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    4ms
    Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2) (clinicaltrials.gov)
    P2/3, N=956, Recruiting, BicycleTx Limited
    New P2/3 trial • Metastases
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • gemcitabine • Bavencio (avelumab) • BT8009
    4ms
    Study SC-101 in Subjects With Advanced Malignancies (clinicaltrials.gov)
    P1, N=100, Not yet recruiting, Tianjin ConjuStar Biologics Co., Ltd.
    New P1 trial • Metastases
    5ms
    Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies (clinicaltrials.gov)
    P1/2, N=329, Recruiting, BicycleTx Limited
    Trial completion date • Trial primary completion date • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • ALK (Anaplastic lymphoma kinase) • PGR (Progesterone receptor) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NECTIN4 (Nectin Cell Adhesion Molecule 4)
    |
    EGFR mutation • ALK fusion • NECTIN4 expression
    |
    Keytruda (pembrolizumab) • BT8009